# OnCo record umbralisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/umbralisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "umbralisib" ;
  schema:name "Umbralisib"@en ;
  schema:description "A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths."@en ;
  schema:url <https://onco.cc/drugs/umbralisib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Umbralisib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27088612> ;
  schema:citation <https://en.wikipedia.org/wiki/Umbralisib> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill" ;
  onco:modality "Oral PI3Kδ / CK1ε inhibitor" ;
  schema:alternateName "Ukoniq" ;
  onco:approval "US 2021: Relapsed marginal zone lymphoma and follicular lymphoma" ;
  onco:acceleratedApproval "US 2021-02-05: Adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20- based regimen", "US 2021-02-05: Adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/tg-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:trials <https://onco.cc/trials/nct03801525/>, <https://onco.cc/trials/nct02793583/>, <https://onco.cc/trials/nct04624633/> .